

# Case–control study examining the association between allopurinol use and ischemic cerebrovascular disease

Shih-Wei Lai,<sup>1,2</sup> Cheng-Li Lin,<sup>1,3</sup> Kuan-Fu Liao<sup>4,5</sup>

<sup>1</sup>College of Medicine, China Medical University, Taichung, Taiwan

<sup>2</sup>Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan

<sup>3</sup>Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan

<sup>4</sup>College of Medicine, Tzu Chi University, Hualien, Taiwan

<sup>5</sup>Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi General Hospital, Taichung, Taiwan

## Correspondence to

Dr Kuan-Fu Liao;  
kuanfuliao@gmail.com

Accepted 25 June 2019  
Published Online First  
24 July 2019

## ABSTRACT

Few studies focus on the relationship between allopurinol and ischemic cerebrovascular disease. The goal of the study was to investigate the association of long-term therapy of allopurinol with the first-time attack of ischemic cerebrovascular disease in Taiwan. We performed a case–control study using the database of the Taiwan National Health Insurance Program. The case group included 14,937 subjects aged 20–84 years with the first-time attack of ischemic cerebrovascular disease from 2000 to 2013. The control group included 14,937 sex-matched and age-matched subjects aged 20–84 years without any type of cerebrovascular disease. Ever use of allopurinol was defined as subjects who had at least a prescription for allopurinol before the index date. The OR and the 95% CI for ischemic cerebrovascular disease associated with allopurinol use were measured by the multivariable logistic regression model. The adjusted OR of ischemic cerebrovascular disease was 0.992 (95% CI 0.989 to 0.996) for subjects with increasing cumulative duration of allopurinol use for every 1 month, compared with never use. In a further analysis, the adjusted OR of ischemic cerebrovascular disease was 0.74 (95% CI 0.57 to 0.96) for cumulative duration of allopurinol use >3 years, compared with never use. Our findings suggest that lone-term therapy of allopurinol >3 years is associated with decreased risk of the first-time attack of ischemic cerebrovascular disease, compared with no allopurinol therapy.

## INTRODUCTION

As well known, hyperuricemia is associated with increased risk of gout. In addition, a large number of epidemiologic studies and meta-analysis have shown that hyperuricemia correlates with increased risk of cerebrovascular disease.<sup>1–5</sup> Allopurinol is widely used to reduce serum uric acid. Few studies investigate the effects of lowering serum uric acid on the risk of cerebrovascular disease. One cohort study showed that allopurinol use correlated with reduced risk of overall cerebrovascular disease (HR 0.91, 95% CI 0.83 to 0.99),<sup>6</sup> but the other cohort study showed that allopurinol use was not statistically associated with the risk of overall cerebrovascular disease (HR 1.18, 95% CI 0.95 to 1.47).<sup>7</sup>

## Significance of this study

### What is already known about this subject?

- ▶ Hyperuricemia correlates with increased risk of cerebrovascular disease.
- ▶ Allopurinol use correlates with reduced risk of overall cerebrovascular disease.

### What are the new findings?

- ▶ Lone-term therapy of allopurinol >3 years is associated with decreased risk of the first-time attack of ischemic cerebrovascular disease, compared with no allopurinol therapy.

### How might these results change the focus of research or clinical practice?

- ▶ Further real-world data can answer whether allopurinol use has the beneficial effects on primary prevention of ischemic cerebrovascular disease among people with hyperuricemia.

Current data from observational studies remain to be conflicting.

Cerebrovascular disease ranked the fourth leading cause of total deaths in Taiwan in 2016 (11,846 deaths due to cerebrovascular disease, 6.87% of total deaths).<sup>8</sup> The prevalence of hyperuricemia was high in Taiwan, 39.4% in men and 17.4% in women.<sup>9</sup> Little is known about the effects of allopurinol use on the risk of ischemic cerebrovascular disease in Taiwan. If the association of allopurinol use with ischemic cerebrovascular disease really exists, more evidence can be given to this issue. A population-based case–control study was performed to investigate the following questions: (1) Is there an association of allopurinol use with ischemic cerebrovascular disease? (2) Is there a duration-dependent effect of allopurinol use?

## METHODS

### Study design and data source

The design and data source of the study were adapted from previous studies.<sup>10–12</sup> A case–control study was performed to analyze the database of the Taiwan National Health Insurance Program. The program was launched in March



© American Federation for Medical Research 2018. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Lai S-W, Lin C-L, Liao K-F. *J Investig Med* 2019;**67**:48–51.

1995 and has covered 99.6% of 23 million people living in the independent country of Taiwan.<sup>13 14</sup>

### Study subjects

The case group included subjects aged 20–84 years with the first-time attack of ischemic cerebrovascular disease from 2000 to 2013. Ischemic cerebrovascular disease included ischemic infarction and transient ischemic attack based on International Classification of Diseases, Ninth Revision, Clinical Modification (codes 433, 434, and 435). We defined the date of diagnosing ischemic cerebrovascular disease as the index date. A random number was appointed for each subject without any type of cerebrovascular disease by generating random numbers between 0 and 1 which were equally distributed. The control group consisted of subjects without any type of cerebrovascular disease who were randomly selected. The case group and the control group were matched for 1:1 ratio and also matched for sex, age (every 5-year interval), comorbidities, and the year of the index date. That is, the enrollment date for the control group was matched for the same year of the case group, but the month and the day were randomly appointed. These statistical criteria were used in previous studies.<sup>15 16</sup>

### Allopurinol exposure

The definition of allopurinol exposure was adapted from previous studies.<sup>17–19</sup> Ever use of allopurinol was defined as subjects who had at least a prescription for allopurinol before the index date. Never use of allopurinol was defined as subjects who did not have a prescription for allopurinol before the index date.

### Comorbidities

The comorbidities which could be potentially associated with ischemic cerebrovascular disease were adapted from previous studies, including alcohol-related disease, atrial fibrillation, chronic kidney disease, chronic obstructive pulmonary disease, coronary artery disease, diabetes mellitus, hyperlipidemia, as well as hypertension.<sup>20 21</sup>

### Statistical analysis

In the beginning, we compared the distributions of demographic status, allopurinol use, and comorbidities between the case group and the control group by using the  $\chi^2$  test for categorical variables, and the t-test for continuous variables. Next step, all variables were included in a univariable logistic regression model. Variables which were found to be statistically significant in a univariable logistic regression model were further included in a multivariable logistic regression model. The OR and the 95% CI for ischemic cerebrovascular disease associated with allopurinol use were measured. Last, we performed the analyses about the duration-dependent and dose-dependent relationship of allopurinol use on the risk of ischemic cerebrovascular disease. All analyses were performed by the SAS statistical software (V.9.2; SAS Institute). The results were considered statistically significant when two-tailed p values were <0.05.

## RESULTS

### Basic information of the study population

There were 14,937 subjects with ischemic cerebrovascular disease in the case group and 14,937 subjects without

**Table 1** Basic information between cases with ischemic cerebrovascular disease and matched controls

Variable	Cases with ischemic cerebrovascular disease n=14,937		Matched controls n=14,937		p Values*
	n	(%)	n	(%)	
Sex					0.61
Female	6676	(44.7)	6720	(45.0)	
Male	8261	(55.3)	8217	(55.0)	
Age group (y)					0.66
20–39	523	(3.5)	499	(3.34)	
40–64	6019	(40.3)	6071	(40.64)	
65–84	8395	(56.2)	8367	(56.02)	
Age (y), mean±SD†	65.6±12.4		64.6±12.0		<0.001
Ever use of allopurinol	1989	(13.3)	1842	(12.3)	0.01
Cumulative duration of allopurinol exposure (mo), median/IQR (Q1–Q3)†	1.50 (0.40–7.00)		2.00 (0.47–8.73)		0.002
Comorbidities*					
Alcohol-related disease	672	(4.5)	717	(4.8)	0.22
Atrial fibrillation	538	(3.6)	495	(3.3)	0.17
Chronic kidney disease	434	(9.6)	1434	(9.6)	0.99
Chronic obstructive pulmonary disease	4464	(29.9)	4438	(29.7)	0.74
Coronary artery disease	7446	(49.9)	7456	(49.9)	0.91
Diabetes mellitus	2826	(18.9)	2878	(19.3)	0.44
Hyperlipidemia	5716	(38.3)	5696	(38.1)	0.81
Hypertension	11 603	(77.7)	11 591	(77.6)	0.87

Data are shown as the number of subjects in each group with percentages given in parentheses.

\* $\chi^2$  test comparing cases with ischemic cerebrovascular disease and matched controls.

†t-test comparing cases with ischemic cerebrovascular disease and matched controls.

**Table 2** Association between ischemic cerebrovascular disease and cumulative duration of allopurinol use

Variable	Case number/control number	Crude OR	(95% CI)	Adjusted OR*	(95% CI)
Never use of allopurinol as a reference	12 948/13 095	1.00	(Reference)	1.00	(Reference)
Cumulative duration of allopurinol use (increase in use duration for every 1 mo)	1989/1842	0.993	(0.989 to 0.997)	0.992	(0.989 to 0.996)
Cumulative duration of allopurinol use (y)					
<1	1652/1468	1.14	(1.06 to 1.23)	1.12	(1.04 to 1.21)
1–3	238/242	1.00	(0.83 to 1.19)	0.97	(0.81 to 1.16)
>3	99/132	0.76	(0.58 to 0.99)	0.74	(0.57 to 0.96)

\*Variables which were found to be statistically significant in a univariable logistic regression model were further tested by a multivariable logistic regression model. Only age could be included for adjustment.

any type of cerebrovascular disease in the control group (table 1). The mean ages (SD) were 65.6 (12.4) years in the case group and 64.6 (12.0) years in the control group. Because the age matching was done by groups with large age range, statistical significance was noted in mean age (t-test,  $p < 0.001$ ). The cumulative duration for allopurinol exposure for the case group was shorter than the duration for the control group, with statistical significance (t-test,  $p = 0.002$ ). Due to the matched case–control study design, there was no significant difference in comorbidities between the case group and the control group ( $X^2$  test,  $p > 0.05$ ). The case group had a higher proportion of ever use of allopurinol than the control group (13.3% vs 12.3%,  $X^2$  test,  $p = 0.01$ ).

#### Association between ischemic cerebrovascular disease and cumulative duration of allopurinol use

The multivariable logistic regression model showed that the adjusted OR of ischemic cerebrovascular disease was 0.992 (95% CI 0.989 to 0.996) for subjects with increasing cumulative duration of allopurinol use for every 1 month, compared with never use. In a further analysis, the adjusted ORs of ischemic cerebrovascular disease were 1.12 (95% CI 1.04 to 1.21) for cumulative duration of allopurinol use <1 year, 0.97 (95% CI 0.81 to 1.16) for 1–3 years, and 0.74 (95% CI 0.57 to 0.96) for >3 years, respectively, compared with never use (table 2).

#### Association between ischemic cerebrovascular disease and cumulative dosage of allopurinol use among subjects with long-term therapy of allopurinol >3 years

Among subjects with cumulative duration of allopurinol use >3 years, the adjusted OR of ischemic cerebrovascular disease was 1.10 (95% CI 0.78 to 1.55) for subjects with increasing cumulative dosage of allopurinol use for every 50 mg, compared with never use (table 3). The dose-dependent effect of allopurinol use on the risk of ischemic cerebrovascular disease did not reach statistical significance.

**Table 3** Association between ischemic cerebrovascular disease and cumulative dosage of allopurinol use among subjects with long-term therapy of allopurinol >3 y

Variable	Case number/control number	Crude OR	(95% CI)	Adjusted OR*	(95% CI)
Never use of allopurinol as a reference	12 948/13 095	1.00	(Reference)	1.00	(Reference)
Cumulative dosage of allopurinol use (increase in dosage for every 50 mg)	99/132	1.10	(0.78 to 1.55)	1.10	(0.78 to 1.55)

\*Variables which were found to be statistically significant in a univariable logistic regression model were further tested by a multivariable logistic regression model. Only age could be included for adjustment.

#### DISCUSSION

We noted that long-term therapy of allopurinol >3 years was associated with decreased odds of ischemic cerebrovascular disease, compared with no allopurinol therapy. There was a duration-dependent effect of allopurinol use on the risk reduction of ischemic cerebrovascular disease. These findings were compatible with previous cohort studies showing that allopurinol use was associated with risk reduction of ischemic cerebrovascular disease.<sup>6,22</sup> The risk would be further decreased for those with long duration of allopurinol use.<sup>6</sup>

The underlying mechanisms about the association of allopurinol use with ischemic cerebrovascular disease cannot be examined in our observational study. A randomized, double-blind, placebo-controlled study showed that allopurinol use could reduce the central blood pressure and the carotid intima-media thickness among subjects with recent ischemic cerebrovascular disease.<sup>23</sup> This at least partially explains that allopurinol use has the beneficial effects on ischemic cerebrovascular disease. In addition, allopurinol use can improve endothelial function,<sup>24,25</sup> which could also have the beneficial effects on ischemic cerebrovascular disease.

Some limitations should be discussed. First, the large sample size of our study can provide statistical significance for a point estimate that is very vulnerable to being influenced by methodological decisions, such as a case–control study design. Further real-world data can answer whether allopurinol use has the beneficial effects on primary prevention of ischemic cerebrovascular disease among people with hyperuricemia. Second, due to the limitation of the database studied, the status of cigarette smoking was not recorded. We included chronic obstructive pulmonary disease and coronary artery disease as a surrogate. Third, the cumulative duration for allopurinol exposure for the case group was shorter than the duration for the control group. The time-window bias found in a case–control

study potentially existed. Interpretation of our data should be cautious. Despite the above limitations, this is the first population-based case–control study to investigate the association of allopurinol use with the first-time attack of ischemic cerebrovascular disease in Taiwan.

Our findings suggest that lone-term therapy of allopurinol >3 years is associated with decreased risk of the first-time attack of ischemic cerebrovascular disease, compared with no allopurinol therapy.

**Contributors** SWL contributed to the conception of the article, initiated the draft of the article, and revised the article. CLL and KFL conducted data analysis and participated in data interpretation.

**Funding** This study was supported in part by the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-212-123004) and China Medical University Hospital (DMR-107-192).

**Disclaimer** The funding agencies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests** None declared.

**Patient consent** Not required.

**Ethics approval** This study was approved by the Research Ethics Committee of China Medical University and Hospital in Taiwan (CMUH-104-REC2-115).

**Provenance and peer review** Not commissioned; externally peer reviewed.

## REFERENCES

- 1 Longo-Mbenza B, Luila EL, Mbete P, *et al.* Is hyperuricemia a risk factor of stroke and coronary heart disease among Africans? *Int J Cardiol* 1999;71:17–22.
- 2 Chao TF, Liu CJ, Chen SJ, *et al.* Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation—could it refine clinical risk stratification in AF? *Int J Cardiol* 2014;170:344–9.
- 3 Yang XL, Kim Y, Kim TJ, *et al.* Association of serum uric acid and cardioembolic stroke in patients with acute ischemic stroke. *J Neurol Sci* 2016;370:57–62.
- 4 Mapoure YN, Ayeah CM, Doualla MS, *et al.* Serum Uric Acid Is Associated with Poor Outcome in Black Africans in the Acute Phase of Stroke. *Stroke Res Treat* 2017;2017:1–9.
- 5 Kim SY, Guevara JP, Kim KM, *et al.* Hyperuricemia and risk of stroke: a systematic review and meta-analysis. *Arthritis Rheum* 2009;61:885–92.
- 6 Singh JA, Yu S. Allopurinol and the risk of stroke in older adults receiving medicare. *BMC Neurol* 2016;16:164.
- 7 Kok VC, Horng JT, Chang WS, *et al.* Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. *PLoS One* 2014;9:e99102.
- 8 Ministry of Health and Welfare Taiwan. statistics of causes of death. 2016. [cited on 1 May 2018, English version] <http://www.mohw.gov.tw/EN/Ministry/Index.aspx>.
- 9 Lai SW, Liu CS, Lin T, *et al.* Prevalence of gout and hyperuricemia in Taiwan: a hospital-based, cross-sectional study. *South Med J* 2009;102:772–3.
- 10 Lai SW, Liao KF, Liao CC, *et al.* Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. *Medicine* 2010;89:295–9.
- 11 Hung SC, Liao KF, Hung HC, *et al.* Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study. *Fam Pract* 2018;35:166–71.
- 12 Lin HF, Liao KF, Chang CM, *et al.* Correlation between proton pump inhibitors and risk of pyogenic liver abscess. *Eur J Clin Pharmacol* 2017;73:1019–25.
- 13 Ministry of Health and Welfare Taiwan. Taiwan Health and Welfare Report. 2016. [cited on 1 May 2018, English version] <http://www.mohw.gov.tw>.
- 14 Lai SW, Lin CL, Liao KF. Risk of contracting pneumonia among patients with predialysis chronic kidney disease: a population-based cohort study in Taiwan. *Biomedicine* 2017;7:20–47.
- 15 Lai SW, Lin CL, Liao KF. Use of Oral Corticosteroids and Risk of Hip Fracture in the Elderly in a Case-Control Study. *Front Pharmacol* 2017;8:625.
- 16 Lai S-W, Lin C-H, Lin C-L, *et al.* Proton pump inhibitors therapy and the risk of hip fracture in older people in Taiwan. *Eur Geriatr Med* 2018;9:169–74.
- 17 Lin HF, Liao KF, Chang CM, *et al.* Statin use correlates with reduced risk of chronic osteomyelitis: a nationwide case-control study in Taiwan. *Curr Med Res Opin* 2017;33:2235–40.
- 18 Lai SW, Lin CL, Liao KF. Association between oral corticosteroid use and pyogenic liver abscesses in a case-control study. *Biomedicine* 2018;8:5–39.
- 19 Lin HF, Liao KF, Chang CM, *et al.* Use of thiazolidinediones and risk of hip fracture in old people in a case-control study in Taiwan. *Medicine* 2017;96:e7712.
- 20 Lai SW, Lin HF, Lin CL, *et al.* Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes: A case-control study in Taiwan. *Medicine* 2016;95:e4455.
- 21 Wong TS, Liao KF, Lin CM, *et al.* Chronic Pancreatitis Correlates With Increased Risk of Cerebrovascular Disease: A Retrospective Population-Based Cohort Study in Taiwan. *Medicine* 2016;95:e3266.
- 22 MacIsaac RL, Salatzki J, Higgins P, *et al.* Allopurinol and Cardiovascular Outcomes in Adults With Hypertension. *Hypertension* 2016;67:HYPERTENSIONAHA.115.06344–540.
- 23 Higgins P, Walters MR, Murray HM, *et al.* Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. *Heart* 2014;100:1085–92.
- 24 Yiginer O, Ozcelik F, Inanc T, *et al.* Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome. *Clin Res Cardiol* 2008;97:334–40.
- 25 Meléndez-Ramírez G, Pérez-Méndez O, López-Osorio C, *et al.* Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia. *Endocr Res* 2012;37:1–6.